-+ 0.00%
-+ 0.00%
-+ 0.00%
Zejing Pharmaceutical (688266.SH): Mid-clinical trial analysis of ZG006 in the treatment of advanced small cell lung cancer patients reached the predetermined main end point
Share
Listen to the news

Zhitong Finance App News, Zejing Pharmaceutical (688266.SH) issued an announcement. Recently, a randomized controlled key clinical trial of ZG006 (INN name: Alveltamig) single-drug injection with a class 1 new drug developed independently by the company to treat patients with advanced small cell lung cancer who have relapsed or progressed after platinum-containing chemotherapy and at least 1 other system treatment (third line and above) completed a pre-set mid-term analysis. The Independent Data Monitoring Committee (IDMC) determined that the trial had reached the intended main end point after reviewing the results. The company will submit a pre-BLA (Biologics License Application) communication application to the Drug Evaluation Center (CDE) of the China Drug Administration and accelerate the marketing process of injectable ZG006.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending